Heart FailureNCT01944813
Advance Care Planning: A Way to Improve End-of-life Care Life Care
A study testing ACp conversation in people with Heart Failure and Pulmonary Disease, run by University of Aarhus at 1 site in Denmark.
Trial summary
Communication about end-of-life issues is often suboptimal. A way to improve the quality of end-of-life care is Advance Care Planning (ACP). ACP is a discussion between an incurable ill patient and the health professionals about preferences for end-of-life care. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure, Pulmonary Disease, Neoplasms
- What is being tested?
- ACp conversation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 360 participants
- Where
- 1 siteDenmark
- Study dates
- Nov 2013to Jul 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Eligible patients from the departments of oncology, cardiology and respiratory medicine at Aarhus University Hospital
- the patient is over 18
- acceptable Danish language skills
Who cannot join
- cognitive impairment
- expected to dy within the next month
- has no relatives
Trial locations and contacts
1 site in 1 country.
Mr. Anders B Jensen, Professor contact
Denmark1 site, 1 recruiting
- Recruiting
Aarhus University
Aarhus, Aarhus, 8000
Mrs. Marianne H Skorstengaard, MD, 28456763 ext. 78462598, mhsk@ki.au.dk
Marianne H Skorstengaard, MD
About this study
Official title: Advance Care Planning: A Way to Improve End-of-life Care
Communication about end-of-life issues is often suboptimal. A way to improve the quality of end-of-life care is Advance Care Planning (ACP). ACP is a discussion between an incurable ill patient and the health professionals about preferences for end-of-life care. In Denmark, there is no tradition of systematic communication with patients about end-of-life care. The aim is to investigate how ACP can be beneficial among incurable ill patients treated in an outpatient context and if the concept is feasible in a Danish context. The study is designed as a prospective randomised controlled trial. Patients from relevant departments will be included and randomised in two groups: one receiving usual care and the other receiving usual care and ACP. Data will be collected from Electronic Patient Files and from questionnaires. If ACP is effective, it will improve the quality of end-of-life care for patients and their families and reduce the psychological distress in the bereaved relatives.
Read the detailed description
Study Design The study is designed as a prospective randomised controlled trial. Eligible patients from the departments of oncology, cardiology and respiratory medicine at Aarhus University Hospital will be included in the study and randomised in two groups: one receiving usual care and the other receiving usual care and ACP. Patients will be recruited from one department at a time, allowing the recruitment period to be up to six months for each department. Because patients with terminal cardiac and respiratory diseases are known to have more unpredictable life expectancy than cancer patients, initial recruitment will be from cardiology and respiratory medicine departments, respectively.9 This procedure will enhance the possibility of the estimated number of deaths in all three diagnose groups to be registered within the study period (see power calculation below). The research group has a long and ongoing close cooperation with the departments mentioned and collaboration has been established.
Practical Execution The researcher (the applicant) will be provided with a list of patients who will attend the outpatient clinic the following day. Using an identification tool (see Appendix 1) the researcher will assess the patients, identifying those patients anticipated to be in need of palliative and supportive care. Patients' data are found in Electronic Patient Files (EPJ). After the patients have been seen by staff in the outpatient's clinic, the researcher will ask the doctor in the clinic whether he/she would be surprised if this patient died within the next 6-12 months. (i.e. "The surprise Question"). 10 If the answer is no, the patient will be enrolled in the study. Within two days hereafter the patient will be contacted by mail and later by telephone. Information about ACP will be given written and verbally. If the patient accepts, informed written consent is obtained. Returning consent form blank or not responding after two reminders will be considered a decline. Patients will be randomised by usual standards; non-research staff will carry out the randomisation using sealed envelopes containing allocation cards assigned by random numbers. All patients included in the study will receive a questionnaire concerning quality of care (see questionnaire data). The patients are also asked to point out a close relative who is likely to accept participation. Participating relatives will be approached in order to fill in questionnaires during the patient's trajectory and in the bereavement period (see questionnaire data).
Intervention Patients in the intervention group will be offered a formal ACP discussion with the researcher. This will be conducted as a discussion between the researcher and the patient based on the Respecting Patient Choices model.11 This programme, developed at the Austin Hospital in Melbourne, Australia, is based on the Respecting Choices programme and involves a coordinated approach to ACP whereby facilitators, in collaboration with the treating doctor, assist patients and their families to reflect on the patient's goals, values, and beliefs, and to discuss and document their future choices about health care. Patients are encouraged to appoint a proxy and to document their preferences about end-of-life care; including the preferences for life prolonging treatments and cardiopulmonary resuscitation recorded on an Advance Care Plan (see Appendix 2). Whenever possible, treating doctors will participate in the discussion to ensure that the patients understand their illness, treatment options, and likely prognosis. The discussion will be audio taped for scientific use and the ACP will be documented in EPJ. The discussion will take place at the hospital or at the patient's home. With the acceptance of the patient, the general practitioner and the community nurse will receive a copy of the ACP documents. Patients will be encouraged to include their closest relative in the ACP discussion. The aim is to complete the ACP discussion within two weeks after the identification of patients in the outpatient's clinic. Consistent with usual practice patients in the control group will receive usual medical and psychosocial care but not a formalised ACP discussion.
Data Collection Demographic data: will be collected at enrolment and will include age, sex, education, children living at home, admission diagnosis, the existence of a form requesting no resuscitation, whether the patient has a proxy, and whether the patient already has any EPJ documented preferences on end-of-life care, including life prolonging treatment or cardiopulmonary resuscitation. Data will be collected from EPJ and in the questionnaires, respectively.
Questionnaire Data A thorough literature review of existing, validated tools will be conducted. Accordingly the questionnaires will be composed by validated and well-established questionnaires and supplemented by ad hoc questions when no existing questionnaires are available. Translation and adaption as well as pilot testing in accordance with international guidelines will be performed before use. All patients will be requested to fill in a questionnaire three to four weeks after inclusion and the relatives are similarly asked to evaluate the care at this time.12 In those cases where the patient dies within the study period, the bereaved relatives will receive a questionnaire evaluating the levels of stress, anxiety and depression as well as a questionnaire concerning the quality of the patient's end-of-life care and preferences for place of care and death.13-15
Power Calculation Based on the existing literature, we expect that the proportion of patients whose end-of-life preferences were known will be 15 % and that an increase to 65 % would represent a clinically meaningful effect. To achieve 90 % power to detect a difference in the primary outcome between groups with a certainty of 95 %, we estimated that 22 deaths would be required in each group, i.e. 44 deaths in total. It is therefore planned to continue the inclusion period until at least 22 deaths are observed in each group among patients enrolled. In a similar study, the population included patients had an average lifespan of 3.5 months the time of inclusion until death and 86 % of included patients died during the study period which was 20 months.16 In order to observe 44 deaths, an estimated inclusion of 90 patients is necessary. The estimated inclusion period will be approximately 18 months.
Perspectives The project is an integrated part of a large research program within the palliative field. The project is, with its focus on creating better trajectories and better treatment for patients throughout the end of their terminal illness, highly relevant. The ongoing development of palliative care and the lack of evidence that characterises the area challenge the health care even more while also dealing with the utilisation of limited financial resources. If ACP is effective in a Danish context, it will improve the end-of-life care for patients and their families and reduce the psychological distress in the bereaved relatives. ACP may therefore contribute to a more rational use of health care resources as well as being a tool to help patients have their preferences met.
Ethics Terminally ill patients are a vulnerable group to involve in research. However, the research group has positive experiences with involving patients and relatives in this kind of research. The patients' main motivation to participate has been to help others in similar situation. It should also be noted that no patients are treated less favourably than the current standard procedure in healthcare. It is optional for patients and their relatives in the intervention group, whether they wish to participate in the ACP or not.
- Conditions
- Heart Failure, Pulmonary Disease, Neoplasms
- Being tested
- ACp conversation
- Keywords
- Advance Care planning, End-of-life Discussions, Questionaires, Palliative Care
- Medical subject headings
- Heart Failure, Lung Diseases, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ACp conversationBehavioural
Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
| Study group | Role | What they receive |
|---|---|---|
| Intervention: ACP conversation | Experimental | Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions. Receives: Behavioral: ACp conversation |
| No intervention: usual care | No intervention | No intervention just usual care |
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of patients who had their preferences regarding place of care and place of death met
Measured: 1.7.2015
Secondary outcomes (1)
Number of re-admissions to hospital from time of inclusion until death
Measured: 1.7.2015
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2013 (estimated)
- Study startNov 2013
- Primary completionJul 2015 (estimated)
- Study completionJul 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by University of AarhusThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 360 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Aarhus
- Sponsor type
- University, hospital or other
- Collaborators
- TrygFonden, Denmark, Danish Cancer Society
- Responsible party
- Sponsor
- Investigators
- Anders B Jensen, Professor, Principal investigator, Department of oncology Aarhus University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01944813
- Sponsor's protocol ID
- 050880
- Status last verified
- Sep 2013
- First submitted
- 6 Sep 2013
- Last updated
- 23 Dec 2014
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Neergaard MA, Skorstengaard MH, Brogaard T, Bendstrup E, Lokke A, Aagaard S, Wiggers H, Andreassen P, Jensen AB. Advance care planning and longer survival in the terminally ill: a randomised controlled trial unexpected finding. BMJ Support Palliat Care. 2020 Jun;10(2):221-222. doi: 10.1136/bmjspcare-2019-001906. Epub 2019 Dec 10. No abstract available.
PubMed 31822479Skorstengaard MH, Jensen AB, Andreassen P, Brogaard T, Brendstrup E, Lokke A, Aagaard S, Wiggers H, Neergaard MA. Advance care planning and place of death, hospitalisation and actual place of death in lung, heart and cancer disease: a randomised controlled trial. BMJ Support Palliat Care. 2020 Dec;10(4):e37. doi: 10.1136/bmjspcare-2018-001677. Epub 2019 Apr 11.
PubMed 30975712
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Advance Care Planning: A Way to Improve End-of-life Care
- ClinicalTrials.gov ID
- NCT01944813
- Acronym / sponsor ID
- 050880
- Conditions
- Heart Failure, Pulmonary Disease, Neoplasms
- Keywords
- Advance Care planning, End-of-life Discussions, Questionaires, Palliative Care
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 360 participants (estimated)
- Lead sponsor
- University of AarhusUniversity, hospital or other
- Collaborators
- TrygFonden, Denmark, Danish Cancer Society
- Study start
- Nov 2013
- Primary completion
- Jul 2015 (estimated)
- Study completion
- Jul 2015 (estimated)
- First posted
- 18 Sep 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Communication about end-of-life issues is often suboptimal. A way to improve the quality of end-of-life care is Advance Care Planning (ACP). ACP is a discussion between an incurable ill patient and the health professionals about preferences for end-of-life care. In Denmark, there is no tradition of systematic communication with patients about end-of-life care. The aim is to investigate how ACP can be beneficial among incurable ill patients treated in an outpatient context and if the concept is feasible in a Danish context. The study is designed as a prospective randomised controlled trial. Patients from relevant departments will be included and randomised in two groups: one receiving usual care and the other receiving usual care and ACP. Data will be collected from Electronic Patient Files and from questionnaires. If ACP is effective, it will improve the quality of end-of-life care for patients and their families and reduce the psychological distress in the bereaved relatives.
Detailed description
Study Design The study is designed as a prospective randomised controlled trial. Eligible patients from the departments of oncology, cardiology and respiratory medicine at Aarhus University Hospital will be included in the study and randomised in two groups: one receiving usual care and the other receiving usual care and ACP. Patients will be recruited from one department at a time, allowing the recruitment period to be up to six months for each department. Because patients with terminal cardiac and respiratory diseases are known to have more unpredictable life expectancy than cancer patients, initial recruitment will be from cardiology and respiratory medicine departments, respectively.9 This procedure will enhance the possibility of the estimated number of deaths in all three diagnose groups to be registered within the study period (see power calculation below). The research group has a long and ongoing close cooperation with the departments mentioned and collaboration has been established.
Practical Execution The researcher (the applicant) will be provided with a list of patients who will attend the outpatient clinic the following day. Using an identification tool (see Appendix 1) the researcher will assess the patients, identifying those patients anticipated to be in need of palliative and supportive care. Patients' data are found in Electronic Patient Files (EPJ). After the patients have been seen by staff in the outpatient's clinic, the researcher will ask the doctor in the clinic whether he/she would be surprised if this patient died within the next 6-12 months. (i.e. "The surprise Question"). 10 If the answer is no, the patient will be enrolled in the study. Within two days hereafter the patient will be contacted by mail and later by telephone. Information about ACP will be given written and verbally. If the patient accepts, informed written consent is obtained. Returning consent form blank or not responding after two reminders will be considered a decline. Patients will be randomised by usual standards; non-research staff will carry out the randomisation using sealed envelopes containing allocation cards assigned by random numbers. All patients included in the study will receive a questionnaire concerning quality of care (see questionnaire data). The patients are also asked to point out a close relative who is likely to accept participation. Participating relatives will be approached in order to fill in questionnaires during the patient's trajectory and in the bereavement period (see questionnaire data).
Intervention Patients in the intervention group will be offered a formal ACP discussion with the researcher. This will be conducted as a discussion between the researcher and the patient based on the Respecting Patient Choices model.11 This programme, developed at the Austin Hospital in Melbourne, Australia, is based on the Respecting Choices programme and involves a coordinated approach to ACP whereby facilitators, in collaboration with the treating doctor, assist patients and their families to reflect on the patient's goals, values, and beliefs, and to discuss and document their future choices about health care. Patients are encouraged to appoint a proxy and to document their preferences about end-of-life care; including the preferences for life prolonging treatments and cardiopulmonary resuscitation recorded on an Advance Care Plan (see Appendix 2). Whenever possible, treating doctors will participate in the discussion to ensure that the patients understand their illness, treatment options, and likely prognosis. The discussion will be audio taped for scientific use and the ACP will be documented in EPJ. The discussion will take place at the hospital or at the patient's home. With the acceptance of the patient, the general practitioner and the community nurse will receive a copy of the ACP documents. Patients will be encouraged to include their closest relative in the ACP discussion. The aim is to complete the ACP discussion within two weeks after the identification of patients in the outpatient's clinic. Consistent with usual practice patients in the control group will receive usual medical and psychosocial care but not a formalised ACP discussion.
Data Collection Demographic data: will be collected at enrolment and will include age, sex, education, children living at home, admission diagnosis, the existence of a form requesting no resuscitation, whether the patient has a proxy, and whether the patient already has any EPJ documented preferences on end-of-life care, including life prolonging treatment or cardiopulmonary resuscitation. Data will be collected from EPJ and in the questionnaires, respectively.
Questionnaire Data A thorough literature review of existing, validated tools will be conducted. Accordingly the questionnaires will be composed by validated and well-established questionnaires and supplemented by ad hoc questions when no existing questionnaires are available. Translation and adaption as well as pilot testing in accordance with international guidelines will be performed before use. All patients will be requested to fill in a questionnaire three to four weeks after inclusion and the relatives are similarly asked to evaluate the care at this time.12 In those cases where the patient dies within the study period, the bereaved relatives will receive a questionnaire evaluating the levels of stress, anxiety and depression as well as a questionnaire concerning the quality of the patient's end-of-life care and preferences for place of care and death.13-15
Power Calculation Based on the existing literature, we expect that the proportion of patients whose end-of-life preferences were known will be 15 % and that an increase to 65 % would represent a clinically meaningful effect. To achieve 90 % power to detect a difference in the primary outcome between groups with a certainty of 95 %, we estimated that 22 deaths would be required in each group, i.e. 44 deaths in total. It is therefore planned to continue the inclusion period until at least 22 deaths are observed in each group among patients enrolled. In a similar study, the population included patients had an average lifespan of 3.5 months the time of inclusion until death and 86 % of included patients died during the study period which was 20 months.16 In order to observe 44 deaths, an estimated inclusion of 90 patients is necessary. The estimated inclusion period will be approximately 18 months.
Perspectives The project is an integrated part of a large research program within the palliative field. The project is, with its focus on creating better trajectories and better treatment for patients throughout the end of their terminal illness, highly relevant. The ongoing development of palliative care and the lack of evidence that characterises the area challenge the health care even more while also dealing with the utilisation of limited financial resources. If ACP is effective in a Danish context, it will improve the end-of-life care for patients and their families and reduce the psychological distress in the bereaved relatives. ACP may therefore contribute to a more rational use of health care resources as well as being a tool to help patients have their preferences met.
Ethics Terminally ill patients are a vulnerable group to involve in research. However, the research group has positive experiences with involving patients and relatives in this kind of research. The patients' main motivation to participate has been to help others in similar situation. It should also be noted that no patients are treated less favourably than the current standard procedure in healthcare. It is optional for patients and their relatives in the intervention group, whether they wish to participate in the ACP or not.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention: ACP conversation | Experimental | Behavioral: ACp conversationIntervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions. |
| No intervention: usual care | No intervention | –No intervention just usual care |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Eligible patients from the departments of oncology, cardiology and respiratory medicine at Aarhus University Hospital
- the patient is over 18
- acceptable Danish language skills
Key exclusion criteria (3 listed)
- cognitive impairment
- expected to dy within the next month
- has no relatives
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ACp conversationIntervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions. | Behavioural | Intervention: ACP conversation |
Primary outcome
The proportion of patients who had their preferences regarding place of care and place of death met
Time frame: 1.7.2015
1 secondary outcome
Number of re-admissions to hospital from time of inclusion until death
Time frame: 1.7.2015
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2014.
- Derived from this study: PubMed 31822479Neergaard MA, Skorstengaard MH, Brogaard T, Bendstrup E, Lokke A, Aagaard S, Wiggers H, Andreassen P, Jensen AB. Advance care planning and longer survival in the terminally ill: a randomised controlled trial unexpected finding. BMJ Support Palliat Care. 2020 Jun;10(2):221-222. doi: 10.1136/bmjspcare-2019-001906. Epub 2019 Dec 10. No abstract available.
- Derived from this study: PubMed 30975712Skorstengaard MH, Jensen AB, Andreassen P, Brogaard T, Brendstrup E, Lokke A, Aagaard S, Wiggers H, Neergaard MA. Advance care planning and place of death, hospitalisation and actual place of death in lung, heart and cancer disease: a randomised controlled trial. BMJ Support Palliat Care. 2020 Dec;10(4):e37. doi: 10.1136/bmjspcare-2018-001677. Epub 2019 Apr 11.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mr. Anders B Jensen, Professor contact
Anders B Jensen, Professor principal investigator
Department of oncology Aarhus University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing ACp conversation in people with Heart Failure and Pulmonary Disease, run by University of Aarhus at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mrs. Marianne H Skorstengaard, MD (28456763 ext. 78462598, mhsk@ki.au.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of patients who had their preferences regarding place of care and place of death met (time frame: 1.7.2015). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01944813, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2014.